RESUMO
Horses are large non-ruminant herbivores and rely on microbial fermentation for energy, with more than half of their maintenance energy requirement coming from microbial fermentation occurring in their enlarged caecum and colon. To achieve that, the gastro-intestinal tract (GIT) of horses harbors a broad range of various microorganisms, differing in each GIT segment, which are essential for efficient utilization of feed, especially to use nutrients that are not or little degraded by endogenous enzymes. In addition, like in other animal species, the GIT microbiota is in permanent interplay with the host's cells and is involved in a lot of functions among which inflammation, immune homeostasis, and energy metabolism. As for other animals and humans, the horse gut microbiome is sensitive to diet, especially consumption of starch, fiber, and fat. Age, breeds, stress during competitions, transportation, and exercise may also impact the microbiome. Because of its size and its complexity, the equine GIT microbiota is prone to perturbations caused by external or internal stressors that may result in digestive diseases like gastric ulcer, diarrhea, colic, or colitis, and that are thought to be linked with systemic diseases like laminitis, equine metabolic syndrome or obesity. Thus, in this review we aim at understanding the common core microbiome -in terms of structure and function- in each segment of the GIT, as well as identifying potential microbial biomarkers of health or disease which are crucial to anticipate putative perturbations, optimize global practices and develop adapted nutritional strategies and personalized nutrition.
RESUMO
The objective of this experiment was to evaluate the influence of an active live yeast direct-fed microbial (DFM) product on receiving and backgrounding period growth performance and efficiency of dietary net energy (NE) utilization in low health risk beef steers. Maine-Anjou × Angus steers (n = 199; body weight [BW] = 252 ± 32.1 kg) were received from two sources at the Ruminant Nutrition Center in Brookings, SD, in November 2019 and used in a 77-d feedlot receiving and backgrounding experiment. Steers were provided access to long-stem hay and ad libitum water upon arrival. Steers were weighed, vaccinated for respiratory pathogens (source 2 only): infectious bovine rhinotracheitis, bovine viral diarrhea types 1 and 2, parainfluenza-3 virus, and bovine respiratory syncytial virus (Bovi-Shield Gold 5, Zoetis, Parsippany, NJ) vaccinated for clostridial species (Ultrabac 7/Somubac, Zoetis) and pour-on moxidectin (Cydectin, Bayer, Shawnee Mission, KS). Steers (n = 176 steers; initial unshrunk BW = 235 ± 27.6 kg) were allotted to pens (n = 20 pens; 10 pens per treatment; eight or nine steers per pen). Diets were based upon corn silage, dry-rolled corn, and dried distillers grains; dietary treatments were 1) no DFM (CON) and 2) DFM (Levucell SC, Advantage Titan, CNCM l-1077), fed at 10 g/steer/d providing 8 × 109 CFU of active live yeast to each steer daily (DFM). Initial BW was the average of day -1 and day 1 BW (n = 176 steers; initial BW = 253 ± 27.6 kg). On day 21, steers received a 200-mg progesterone and 20-mg estradiol benzoate implant. Data were analyzed from day 1 to 47 (receiving period), day 48 to 77, and from day 1 to 77 as a randomized complete block design; pen served as the experimental unit for all analyses. On day 47 of the experiment, DFM had greater BW (P = 0.01) by 0.9% and average daily gain (ADG; P = 0.01) by 4.2% and gain-to-feed ratio (G:F) tended (P = 0.13) to be 2.8% greater. Day 77 BW did not differ (P = 0.60), cumulative (days 1-77): ADG (P = 0.47), dry matter intake (P = 0.66), and G:F (P = 0.56) were similar. Yeast inclusion had no appreciable influence on performance-based dietary NE utilization or the ratio of observed/expected dietary NE (P ≥ 0.59). In low health risk steers, DFM improved performance during the feedlot receiving period. However, no improvements for DFM were detected for cumulative performance from day 1 to 77. The confirmation of yeast counts indicated the CFU to be above the expected level at the start of the trial but was found below expected level at the end of the trial. This may explain differences during the initial 47 d compared to cumulative growth performance results.